Skip to main content
SpringerLink
Log in

Lanreotide for the treatment of acromegaly

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Lanreotide is an eight-amino acid peptide, which is an analog of the native somatostatin peptide, physiological inhibitor of growth hormone (GH). The drug shows high binding affinity for somatostatin receptors, SSTR2 and SSTR5, which is the primary mechanism considered to be responsible for decreasing GH secretion and GH cell proliferation in acromegaly. Two different formulations of lanreotide are currently available: lanreotide slow release, which requires intramuscular injection every 7–14 days, and lanreotide autogel, which requires deep subcutaneous injection every 4–8 weeks. Several studies have been published to date on the use of lanreotide in acromegaly. Antisecretory efficacy has been reported in 35%–70% of cases; this huge variability is probably explained by different indications (eg, primary or adjunctive postsurgical treatment), or the fact that some studies were based on patients known to be responders to somatostatin analogs. As a primary treatment, antisecretory efficacy was very similar, confirming the possibility of lanreotide as an option in cases of unsuccessful surgery, contraindication, or surgery refusal. Lanreotide also has antitumoral effects as it induces a decrease in tumor volume of 〉25% in 30%–70% of patients. This could be beneficial before transsphenoidal surgery, as a pretreatment, to decrease tumor volume and ease surgery; however, to date, advantages in terms of final remission or uncured status remain a matter of debate. Side effects are rare; the most frequent being gastrointestinal discomfort and increased risk of gallstone formation, and glucose metabolism modifications. Comparison with the other somatostatin analog, octreotide, tends to show identical levels of efficacy between both drugs. Lanreotide thus seems to be an effective treatment in acromegaly. To date, however, lanreotide is still considered as only suspending GH secretion, thus requiring prolonged and costly treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509–1517.

    Article  CAS  PubMed  Google Scholar 

  2. Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;3:17.

    Article  PubMed  Google Scholar 

  3. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93:61–67.

    Article  CAS  PubMed  Google Scholar 

  4. Brazeau P, Guillemin R. Editorial: Somatostatin: newcomer from the hypothalamus. N Engl J Med. 1974;290:963–964.

    CAS  PubMed  Google Scholar 

  5. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988;9:417–436.

    Article  CAS  PubMed  Google Scholar 

  6. Saveanu A, Jaquet P, Brue T, Barlier A. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol Cell Endocrinol. 2008;286:206–213.

    Article  CAS  PubMed  Google Scholar 

  7. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28–47.

    Article  CAS  PubMed  Google Scholar 

  8. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966–973.

    Article  CAS  PubMed  Google Scholar 

  9. Ciccarelli A, Daly A, Beckers A. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium. Treat Endocrinol. 2004;3:77–81.

    Article  CAS  PubMed  Google Scholar 

  10. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab. 2001;86:2976–2981.

    Article  CAS  PubMed  Google Scholar 

  11. Molitch ME. Lanreotide Autogel in the management of acromegaly. Drugs. 2008;68:724.

    Article  PubMed  Google Scholar 

  12. Troconiz IF, Cendros JM, Peraire C, et al. Population pharmacokinetic analysis of lanreotide autogel((r)) in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet. 2009;48:51–62.

    Article  CAS  PubMed  Google Scholar 

  13. Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism. 2005;54:1276–1281.

    Article  CAS  PubMed  Google Scholar 

  14. Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol. 2005;63:514–519.

    Article  CAS  Google Scholar 

  15. Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol. 2004;56:471–476.

    Article  CAS  PubMed  Google Scholar 

  16. Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol. 2008;68:343–349.

    CAS  Google Scholar 

  17. Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol. 2007;67:282–289.

    Article  CAS  Google Scholar 

  18. Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of Lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf). 2008 Dec 15 [Epub ahead of print]

  19. Attanasio R, Lanzi R, Losa M, et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract. 2008;14:846–855.

    PubMed  Google Scholar 

  20. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol. 2008;69:299–305.

    Article  CAS  Google Scholar 

  21. Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol. 2006;65:320–326.

    Article  CAS  Google Scholar 

  22. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol. 2006;64:209–214.

    Article  CAS  Google Scholar 

  23. Caron P, Bex M, Cullen DR, et al. One-year followup of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol. 2004;60:734–740.

    Article  CAS  Google Scholar 

  24. Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab. 2003;88:5258–5265.

    Article  CAS  PubMed  Google Scholar 

  25. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab. 2002;87:4142–4146.

    Article  CAS  PubMed  Google Scholar 

  26. Ambrosio MR, Franceschetti P, Bondanelli M, et al. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism. 2002;51:387–393.

    Article  CAS  PubMed  Google Scholar 

  27. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol. 2002;56:65–71.

    Article  CAS  Google Scholar 

  28. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87:99–104.

    Article  CAS  PubMed  Google Scholar 

  29. Cozzi R, Barausse M, Sberna M, et al. Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary. 2000;3:231–238.

    Article  CAS  PubMed  Google Scholar 

  30. Attanasio R, Barausse M, Cozzi R. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest. 2001;24:209–216.

    CAS  PubMed  Google Scholar 

  31. Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab. 2000;85:4099–4103.

    Article  CAS  PubMed  Google Scholar 

  32. Chanson P, Leselbaum A, Blumberg J, Schaison G. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary. 2000;2:269–276.

    CAS  Google Scholar 

  33. Verhelst JA, Pedroncelli AM, Abs R, et al. Slowrelease lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol. 2000;143:577–584.

    Article  CAS  PubMed  Google Scholar 

  34. Colao A, Marzullo P, Ferone D, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest. 1999;22:40–47.

    CAS  PubMed  Google Scholar 

  35. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 1997.82:18–22.

    Article  CAS  PubMed  Google Scholar 

  36. Giusti M, Gussoni G, Cuttica CM, Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab. 1996;81:2089–2097.

    Article  CAS  PubMed  Google Scholar 

  37. Morange I, De Boisvilliers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 1994;79:145–151.

    Article  CAS  PubMed  Google Scholar 

  38. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006;91:2112–2118.

    Article  CAS  PubMed  Google Scholar 

  39. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:4405–4410.

    Article  CAS  PubMed  Google Scholar 

  40. Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2009 Feb 3 [Epub ahead of print].

  41. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93:2957–2968.

    Article  CAS  PubMed  Google Scholar 

  42. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90:4465–4473.

    Article  CAS  PubMed  Google Scholar 

  43. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 1992.117:711–718.

    CAS  PubMed  Google Scholar 

  44. Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol. 2003;58:471–481.

    Article  CAS  Google Scholar 

  45. Cannavo S, Squadrito S, Curto L, Almoto B, Trimarchi F. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res. 2001;33:618–624.

    Article  CAS  PubMed  Google Scholar 

  46. Nemergut EC, Dumont AS, Barry UT, Laws ER. Perioperative management of patients undergoing transsphenoidal pituitary surgery. Anesth Analg. 2005;101:1170–1181.

    Article  PubMed  Google Scholar 

  47. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008;93:2984–2990.

    Article  CAS  PubMed  Google Scholar 

  48. Baldelli R, Ferretti E, Jaffrain-Rea ML, et al. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab. 1999.84:527–532.

    Article  CAS  PubMed  Google Scholar 

  49. Hradec J, Kral J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol. 1999;83:1506–1509.

    Article  CAS  PubMed  Google Scholar 

  50. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S. Improvement of left ventricular hypertrophy and arrhythmias after lanreotideinduced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest. 2002;25:971–976.

    CAS  PubMed  Google Scholar 

  51. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007;92:1743–1747.

    Article  CAS  PubMed  Google Scholar 

  52. Ertorer ME, Bakiner O, Anaforoglu I, Bozkirli E, Tutuncu NB, Demirag NG. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. Neuroendocrinol Lett. 2007;28:727–733.

    CAS  PubMed  Google Scholar 

  53. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol. 2006;155:73–78.

    Article  CAS  PubMed  Google Scholar 

  54. Baldelli R, Battista C, Leonetti F, et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol. 2003;59:492–499.

    Article  CAS  Google Scholar 

  55. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94:1500–1508.

    Article  CAS  PubMed  Google Scholar 

  56. Paisley AN, Roberts ME, Trainer PJ. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol. 2007;66:723–726.

    Article  CAS  Google Scholar 

  57. Turner HE, Lindsell DR, Vadivale A, Thillainayagam AV, Wass JA. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly. Eur J Endocrinol. 1999;141:590–594.

    Article  CAS  PubMed  Google Scholar 

  58. Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol. 2007;67:512–519.

    CAS  Google Scholar 

  59. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151:317–324.

    Article  CAS  PubMed  Google Scholar 

  60. van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol. 2004;150:489–495.

    Article  PubMed  Google Scholar 

  61. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol. 2004;150:473–480.

    Article  CAS  PubMed  Google Scholar 

  62. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol. 2008;68:473–480.

    CAS  Google Scholar 

  63. Castinetti F, Morange I, Dubois N, et al. Does firstline surgery still have its place in the treatment of acromegaly? Ann Endocrinol. 2009;70:107–112.

    Article  CAS  Google Scholar 

  64. Bates PR, Carson MN, Trainer PJ, Wass JA. Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol. 2008;68:136–142.

    Article  CAS  Google Scholar 

  65. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab. 2005;90:4483–4488.

    Article  CAS  PubMed  Google Scholar 

  66. Castinetti F, Morange I, Dufour H, Regis J, Brue T. Radiotherapy and radiosurgery in acromegaly. Pituitary. 2009;12:3–10.

    Article  PubMed  Google Scholar 

  67. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol. 2004;61:209–215.

    Article  CAS  Google Scholar 

  68. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007;92:4598–4601.

    Article  CAS  PubMed  Google Scholar 

  69. Neggers S, de Herder W, Janssen J, Feelders R, Van der Lely A. Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: long-term safety up to 4.5 years (median 2.2 yrs) of follow-up in 86 patients. Eur J Endocrinol. 2009;160:529–533.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Université de la Méditerranée and Centre de Référence des Maladies Rares d’Origine Hypophysaire, Hôpital de la Timone, Assistance Publique Hôpitaux de Marseille, Marseille, France

    F. Castinetti, A. Saveanu, I. Morange & T. Brue

Authors
  1. F. Castinetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Saveanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Morange
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Brue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Brue.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castinetti, F., Saveanu, A., Morange, I. et al. Lanreotide for the treatment of acromegaly. Adv Therapy 26, 600–612 (2009). https://doi.org/10.1007/s12325-009-0035-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0035-4

Keywords

Search

Navigation